Search Results

You are looking at 71 - 80 of 444 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Feng Lin, Jinlin Song, Melissa Pavilack, Jipan Xie, Catherine Fernan, Ahmed Noman, and Winghan Jacqueline Kwong

patients who used TBR as 1L, 130 initiated 2L treatment and trastuzumab was used again as 2L in 72 patients. The most common regimens used in 2L post 1L TBR were paclitaxel + ramucirumab (15.4%), FOLFOX + trastuzumab (11.5%), and capecitabine + trastuzumab

Full access

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter

doublet and triplet chemotherapy regimens (ie, cisplatin/paclitaxel, carboplatin/paclitaxel, topotecan/paclitaxel, and topotecan/paclitaxel/bevacizumab) were restratified according to the NCCN Categories of Preference. In addition, emerging data on a new

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

measuring less than 1 cm after debulking, survival was increased by 16 months after IP therapy using cisplatin/paclitaxel when compared with standard intravenous therapy (65.6 vs 49.7 months; P =.03). 15 Recent long-term follow-up data have confirmed this

Full access

Presenter: Eileen M. O’Reilly

gemcitabine plus albumin-bound (nab)-paclitaxel, based on the disappointing results of the recent APACT trial. 7 Consensus is lacking for adjuvant chemotherapy plus radiation, which is being studied in the phase III RTOG 0848 trial and for which results are

Full access

Philip E. Lammers and Leora Horn

randomized phase III trial comparing carboplatin/paclitaxel with or without bevacizumab in 878 patients with recurrent or advanced nonsquamous NSCLC. 9 Improvements in median overall survival (OS), median progression-free survival (PFS), and response rate

Full access

Kohei Shitara and Atsushi Ohtsu

care was associated with significantly improved OS in patients with disease progression on first-line chemotherapy. 9 Moreover, ramucirumab plus paclitaxel chemotherapy significantly increased OS compared with paclitaxel alone in patients after first

Full access

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes

combined with bevacizumab/carboplatin/paclitaxel (ABCP) versus bevacizumab/chemotherapy for patients with metastatic nonsquamous NSCLC. 17 Median OS was 19.2 months (95% CI, 17.0–23.8) in the ABCP arm compared with 14.7 months (95% CI, 13.3–16.9) for

Full access

circumstances” to “other recommended”: ► Capecitabine ► Gemcitabine + nab-paclitaxel modified schedule (category 2B) ► Gemcitabine single agent (category 2B) • FOLFIRI (preferred regimen) was removed and replaced with 5-FU ± irinotecan (useful in

Full access

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck

Full access

Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray

carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecolog Oncology Group study (Abstr 1) . Gynecol Oncol 2003 ; 88 : 156 . 9 Ayhan A Tuncer ZS Tuncer R . Is routine appendectomy beneficial in the